

Supplementary Table 3. Clinical, demographic and immunological associations of increased serum IL-8 levels in in AQP4 and MOG autoantibody associated demyelinating diseases (without anti-NMDAR encephalitis).

Parameters	AQP4-Ab		MOG-Ab	
	Serum IL-8 levels < 3.7 pg/ml	Serum IL-8 levels ≥ 3.7 pg/ml	Serum IL-8 levels < 3.7 pg/ml	Serum IL-8 levels ≥ 3.7 pg/ml
Number of cases	3	17	9	18
MOG-Ab titre (1:) ¹	na	na	480 (160-1280)	1280 (160-81920)
Females	3/3 (100%)	16/17 (94%)	6/9 (67%)	7/18 (39%)
Age (years) ¹	55 (52-62)	49.5 (19-83)	26 (4-51)	18.5 (1-68)
Children	0/3 (0%)	0/17 (0%)	2/9 (22%)	9/18 (50%)
Disease duration (months)	1 (0-94)	1 (0-27)	0 (0-264)	7 (0-156)
Acute phase ²	3/3 (100%)	12/12 (100%)	8/8 (100%)	5/5 (100%)
Clinical presentation ³				
ON	1/3 (33%)	2/16 (12.5%)	0/8 (0%)	5/17 (29%)
TM	2/3 (67%)	7/16 (44%)	5/8 (62.5%)	4/17 (23.5%)
ON+TM	0/3 (0%)	5/16 (31%)	1/8 (12.5%)	3/17 (18%)
Brain stem	0/3 (0%)	1/16 (6%)		
Cerebral	0/3 (0%)	1/16 (6%)	2/8 (25%)	5/17 (29%)
Diagnosis NMOSD ⁴	3/3 (100%)	16/16 (100%)	0/9 (0%)	2/18 (11%)
CSF cells ¹	4 (1-1758)	10 (0-182)	48 (2-192)	2 (0-180)
CSF proteins (mg/dl) ¹	84 (32-141)	56 (30-499)	42 (30-120)	30 (19-124)
Data are shown as ¹ median (range); ² data available from 28 patients; ³ data available from 44 patients; ⁴ data available from 46 patients.				